 AstraZeneca PLC LSE:AZN reported an unsuccessful phase-three clinical for a new treatment to help with a condition of the oesophagus. The late-stage MESSINA study of the companys Fasrena drug in eosinophilic esophagitis did not meet one of the two dual primary endpoints, as it failed to show an improvement in problems with swallowing, also known as dysphagia, compared to placebo. 